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Abstract 
Background: Epithelial mesenchymal transition (EMT) is tightly regulated by a network of transcription factors 
(EMT-TFs). Among them is the nuclear factor ZEB2, a member of the zinc-finger E-box binding homeobox family. 
ZEB2 nuclear localization has been identified in several cancer types, and its overexpression is correlated with the 
malignant progression. ZEB2 transcriptionally represses epithelial genes, such as E-cadherin (CDH1), by directly bind-
ing to the promoter of the genes it regulates and activating mesenchymal genes by a mechanism in which there is 
no full agreement. Recent studies showed that EMT-TFs interact with epigenetic regulatory enzymes that alter the 
epigenome, thereby providing another level of control. The role of epigenetic regulation on ZEB2 function is not well 
understood. In this study, we aimed to characterize the epigenetic effect of ZEB2 repressive function on the regula-
tion of a small Rab GTPase RAB25.
Results: Using cellular models with conditional ZEB2 expression, we show a clear transcriptional repression of RAB25 
and CDH1. RAB25 contributes to the partial suppression of ZEB2-mediated cell migration. Furthermore, a highly 
significant reverse correlation between RAB25 and ZEB2 expression in several human cancer types could be identified. 
Mechanistically, ZEB2 binds specifically to E-box sequences on the RAB25 promoter. ZEB2 binding is associated with 
the local increase in DNA methylation requiring DNA methyltransferases as well as histone deacetylation (H3K9Ac) 
depending on the activity of SIRT1. Surprisingly, SIRT1 and DNMTs did not interact directly with ZEB2, and while SIRT1 
inhibition decreased the stability of long-term repression, it did not prevent down-regulation of RAB25 and CDH1 by 
ZEB2.
Conclusions: ZEB2 expression is resulting in drastic changes at the chromatin level with both clear DNA hypermeth-
ylation and histone modifications. Here, we revealed that SIRT1-mediated H3K9 deacetylation helps to maintain gene 
repression but is not required for the direct ZEB2 repressive function. Targeting epigenetic enzymes to prevent EMT is 
an appealing approach to limit cancer dissemination, but inhibiting SIRT1 activity alone might have limited effect and 
will require drug combination to efficiently prevent EMT.
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Introduction
Epithelial-to-mesenchymal transition (EMT) is an 
important reversible process that occurs during embry-
onic development and in physiological processes during 
adulthood (e.g., wound healing), but it is aberrantly acti-
vated in pathologies such as fibrosis and cancer progres-
sion. During EMT, epithelial cells lose cell polarity and 
acquire a more spindle-shaped mesenchymal morphol-
ogy associated with transcriptional repression of epithe-
lial genes such as E-cadherin (CDH1) and activation of 
mesenchymal genes such as Vimentin (VIM). In tumors, 
cells undergoing EMT become motile, promoting tumor 
invasion and metastasis, as well as stemness and chem-
oresistance, which make them more aggressive and able 
to drive tumor relapse [1, 2].
EMT is a tightly regulated process controlled by a 
network of transcription factors (EMT-TFs), including 
ZEB2, a member of the zinc-finger E-box binding home-
obox (ZEB) family. ZEB2 is overexpressed in several can-
cer types (e.g., breast, ovarian and colorectal cancer) [3] 
which are correlated with metastasis and poor progno-
sis [4–7]. Like other EMT-TFs, ZEB2 represses epithe-
lial genes by directly binding to E-box sequences in the 
promoter of its targeted genes or by activating mesen-
chymal genes through a mechanism that is still debated. 
Over the past few years, an increasing number of stud-
ies have shown that EMT-TFs can interact with many 
epigenetic remodeling enzymes to alter the epigenome 
of cells resulting in another level of gene regulation by 
EMT-TFs [8]. So far, only LSD1, a histone demethyl-
ase [9], and G9A, a histone methyltransferase [10], have 
been reported to interact with ZEB2. The existence of 
other epigenetic partners is suspected, as like in the case 
of other EMT-TFs. However, the importance of such 
nuclear interactions on the repressing/activating func-
tions of EMT-TFs in gene regulation during EMT is still 
not clear.
While CDH1 is a well-known target of EMT-TFs, many 
other genes are regulated during EMT but their regula-
tion and effect on EMT-associated properties are not 
well understood. RAB25 (Rab11c), a small Rab GTPase 
belonging to the Rab11 family, is down-regulated dur-
ing EMT [11, 12]. Physiologically, RAB25 is specifi-
cally expressed in epithelial cells and is involved in the 
intracellular trafficking associated with apical recycling 
and transcytosis [13]. Independent of EMT, RAB25 has 
gained attention because its expression is altered in dif-
ferent human cancer subtypes, but its role in cancer pro-
gression is not clear. Nevertheless, RAB25 seems to be 
tumor specific. Several studies on ovarian cancer [14], 
renal cell carcinoma [15, 16], luminal B breast cancer [12] 
and advanced non-small lung cancer [17] have described 
RAB25 as an oncogene, associated with metastasis and a 
poor prognosis. However, other studies have shown that 
RAB25 is a tumor suppressor that prevents cell migration 
and proliferation in head and neck squamous carcinoma 
[18], colorectal cancer [19, 20] and claudin-low breast 
cancer [12]. In EMT, RAB25 has repeatedly been found 
inversely correlated with EMT-TF [12, 21], suggesting 
that it has a more conserved functional role in epithelial 
differentiation. But little is known about the involvement 
and regulation of RAB25 during EMT.
In this study, we examined RAB25 as a new putative 
EMT regulator during ZEB2-induced EMT and studied 
the transcriptional regulatory mechanism by focusing on 
epigenetic changes.
Results
RAB25 expression is inversely correlated with ZEB2 
expression in several cancer types
In previous studies, we and others have shown by 
genome-wide expression analysis that induction of EMT-
TFs down-regulates RAB25 expression (data not shown; 
[12, 21]). In this study, we specifically examined the 
effect of ZEB2 on tumor cell properties associated with 
differential gene expression. To that end, we generated 
a doxycycline-inducible ZEB2 construct stably trans-
duced into MCF7, A431 and HT29 cell lines which have 
low or no endogenous ZEB2 expression. We found that 
ZEB2 expression correlated with a down-regulation of 
both RAB25 and CDH1 (Fig.  1a) coding for E-cadherin 
and a well-known target of ZEB2 [22]. This confirms the 
relevance of our model for EMT at the molecular level. 
Knocking-down ZEB2 (ZEB2-KD) in the mesenchy-
mal-like MDA-MB-231 breast cancer cell line (which 
expresses more endogenous ZEB2 and less RAB25 than 
MCF7 cells) induced the expression of RAB25 and CDH1 
(Fig. 1b). In RNA from a panel of cell lines of epithelial 
origin, we found a significant reverse correlation between 
ZEB2 and RAB25 expression levels (Fig. 1c). To evaluate 
if this correlation is broadly represented in other cancer 
types, we analyzed the NCI-60 cell line transcriptome 
database and the Cancer Cell Line Encyclopedia (CCLE). 
Indeed we confirmed that RAB25 expression is inversely 
correlated with ZEB2 expression (r = − 0. 60; p < 0.001 
and r = − 0.55; p < 0.001 in the two respective databases) 
indicating the existence of a conserved regulatory mech-
anism (Fig. 1d, e).
The correlation between RAB25 and ZEB2 expres-
sion was strong in breast cancer and colorectal cancer 
cells (respectively, r = − 0.84; p < 0.001 and r = − 0.66; 
p < 0.001, Additional file  1: Fig.  S1a and c), but low in 
pancreatic and small-cell lung cancer cells (respectively, 
r = − 0.39; p < 0.001 and r = − 0.38; p < 0.001, Additional 
file  1: Fig.  S1d and e). Interestingly, most breast cancer 
subtypes expressed a high level of ZEB2 and low level of 
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Fig. 1 ZEB2 and RAB25 expression are inversely correlated. (a, b) Relative mRNA expression of ZEB2, RAB25 and CDH1 measured by qRT-PCR in (a) 
MCF7, HT29 and A431 ZEB2 doxycycline-inducible (+dox) models and b MDA-MB-231 ZEB2 KD (shZEB2). Control values were set to 1, and s.d. is 
shown. P values were determined using unpaired t tests (*p < 0.05;**p < 0.01). Three independent experiments were performed. c ZEB2 and RAB25 
mRNA expression in a epithelial cell line panel. d–e Correlation between ZEB2 (y-axis) and RAB25 (x-axis) expression from publicly available datasets 
from d NCI-60 cell panel and e the Cancer Cell Line Encyclopedia (CCLE). Mean of each parameter was calculated, individual cell type values 
reported to the mean and log2 transformed. Pearson’s correlation test was used to calculate r and p values. f Boxplots showing RAB25 (left panel) 
and ZEB2 (right panel) expression in epithelial (n = 11) and mesenchymal (n = 37) cell lines from NCI-60 cell panel. P values were determined using 
unpaired t tests (***p < 0.001)
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RAB25, except in claudin-low subtype in which RAB25 
has been described as a tumor suppressor (Additional 
file  1: Fig.  S1b). Almost all skin cancer cell lines had 
high expression levels of ZEB2 and low levels of RAB25 
(Additional file 1: Fig. S1f ). In non-small-cell lung cancer 
cells, ZEB2 expression was weak regardless of the RAB25 
expression level (Additional file  1: Fig.  S1g). Grouping 
cell lines from the NCI-60 panel on the basis of their 
epithelial (n = 11) or mesenchymal-like (n = 37) differ-
entiation showed that RAB25 was essentially expressed 
in epithelial cells, while ZEB2 was expressed in mesen-
chymal cells (Fig.  1e). Taken together, these data show 
that RAB25 is likely important in epithelial polarity and 
is potentially transcriptionally repressed by ZEB2 during 
EMT. To study the functional effect of RAB25 attenua-
tion in the context of ZEB2-induced EMT, we performed 
RAB25 rescue experiments. To that end, we condition-
ally induced ZEB2 in MCF7 and A431 cell lines and then 
overexpressed RAB25 to counteract its repression by 
ZEB2 (Fig.  2a, c). Upon ZEB2 induction, cell migration 
was significantly increased (Fig.  2b, d) while the rescue 
of RAB25 expression partially prevented cell migration 
(Fig. 2b, d). Using MDA-MB-231 ZEB2-KD cells, we per-
formed the reverse procedure by blocking RAB25 induc-
tion upon ZEB2 down-regulation using specific shRNAs 
(Fig.  2e). We found a significant decrease in cell migra-
tion, while RAB25 KD along with ZEB2 KD drastically 
increased migration (Fig.  2f ). Together, these data sup-
port the notion that RAB25 represses ZEB2-associated 
cell migration during EMT.
ZEB2 directly binds to E‑box sequences in the RAB25 
promoter
The regulation of RAB25 expression by ZEB2 is not 
well understood, so we studied its transcriptional con-
trol. Based on the results of our previous study, we ana-
lyzed the promoter region of RAB25 from −200 bp to 
+ 17  bp. We identified putative ZEB2 binding sites in 
the RAB25 promoter: two E-box sequences (CANNTC) 
and two Z-box sequences (ATANNTGT), which are 
conserved in several species (Fig.  3a). To study the 
impact of ZEB2 on RAB25 promoter activity, we cloned 
the identified promoter region in a luciferase reporter 
vector. Upon ZEB2 induction, RAB25 promoter activ-
ity was greatly reduced in RAB25-positive cells, while 
the overexpression of ZEB2 harboring mutations in 
both zinc-finger clusters responsible for DNA binding 
failed to repress the activity (Fig. 3b). This result shows 
that ZEB2 binding to DNA is essential for control of 
the RAB25 promoter activity. To examine if the iden-
tified E- and/or Z-boxes are involved in ZEB2 recruit-
ment and to identify which of them are essential, we 
mutated the sites individually and also in different 
combinations. Mutation of E-box  1 or E-box  2 alone 
did not significantly affect RAB25 repression, whereas 
mutation of both of them diminished RAB25 repres-
sion substantially (Fig.  3c). Combining Z-box  1 and 2 
mutations completely reversed the repression (Fig. 3c). 
To confirm at the chromatin level the precise bind-
ing region of ZEB2, we performed ZEB2 chromatin 
immunoprecipitation (ChIP) assays using PCR ampli-
cons covering the entire RAB25 promoter (Fig. 3d). We 
found that ZEB2 was significantly enriched in amplicon 
3, which corresponds to E-box 2 and E-box 1 localiza-
tion (Fig.  3d). We analyzed ZEB2 enrichment at the 
CDH1 and EpCAM promoters as positive controls 
because those genes had been reported to be targeted 
by ZEB factors [11, 23]. As expected, we confirmed the 
enrichment of ZEB2 for both genes (Additional file  2: 
Fig. S2a). Taken together, our results indicate that ZEB2 
directly interacts with E-box sequences in the RAB25 
promoter to repress transcription.
ZEB2 increased DNA methylation at the RAB25 promoter 
through DNMTs activity
An increasing number of studies document the interac-
tion of different EMT-TFs with different combinations of 
epigenetic enzymes and show that the genomes of cells 
going through EMT undergo large shifts in their epig-
enomes. However, the functional contribution of these 
epigenetic alterations during EMT is still under inves-
tigation. To focus on the first epigenetic modifications 
directly caused by ZEB2 activity, we measured DNA 
methylation and different histone marks 24 h after ZEB2 
induction in epithelial cells. Low RAB25 expression has 
been linked with a high DNA methylation level [24–27]. 
We analyzed the RAB25 methylation status using the 
methylome dataset of the NCI-60 cell panel (GSE49143) 
focusing on cell lines previously shown to have a strong 
inverse correlation between ZEB2 and RAB25 (Fig. 1d; 41 
out of 60 cell lines). For three out of four probes, we found 
that ZEB2 expression was directly correlated with a high 
DNA methylation level at the RAB25 promoter (r = 0.782; 
p < 0.001), while RAB25 expression was inversely corre-
lated with the methylation status (r = − 0.973; p < 0.001) 
(Fig. 4a). In our model, ZEB2 induction leads to a strong 
increase in the DNA methylation (Fig. 4b) To specifically 
measure RAB25 DNA methylation controlled by ZEB2, 
we performed a methyl-binding protein assay and ana-
lyzed the RAB25 promoter region. There was a significant 
increase in RAB25 methylation in the presence of ZEB2 
expression, while 5-aza-2′-deoxycytidine (5-aza) treat-
ment prevented methylation (Fig. 4c). This result points 
to a direct role for ZEB2 in RAB25 promoter methylation 
by DNA methyltransferases.
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ZEB2 increased H3K9 deacetylation at the RAB25, CDH1 
and EpCAM promoters through SIRT1 activity
Additionally, we wanted to extend our knowledge of the 
epigenetic regulation of RAB25 by measuring the level of 
several histone marks related to transcriptional activa-
tion (H3K27Ac, H3K4me3 and H3K9Ac) or repression 
(H3K27me3). After ZEB2 induction, H3K4me3 and 
H3K9Ac histone marks decreased substantially, but 
H3K27Ac and H3K27me3 were not affected (Fig.  5a). 
We performed histone ChIP assay and measured the 
enrichment of H3K9Ac, H3K27me3 and H3K4me3 at 
the RAB25 promoter using the same PCR amplicon as in 
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Fig. 2 RAB25 expression reduced ZEB2-driven cell migration. a–d ZEB2 was induced in MCF7 and A431 (+dox), and RAB25 expression was rescued 
by a transiently transfected RAB25 expression construct (+dox/RAB25). a, c mRNA expression level of ZEB2 and RAB25 was analyzed by qRT-PCR 
in (a) MCF7 and c A431. Control values were set to 1, and s.d. is shown. b, d Cell migration was evaluated by a transwell assay with b MCF7 and 
d A431. Results are expressed as the total number of cells counted per chamber. e–f ZEB2 was knocked down in MDA-MB-231 (shZEB2/pLVTH), 
and RAB25 induction was blocked using specific shRNA (shZEB2/shRAB25). e mRNA expression level of ZEB2 and RAB25 was analyzed by qRT-PCR. 
Control values were set to 1, and s.d. is shown. f Cell migration was evaluated by a transwell assay. Results are expressed as the total number of cells 
counted per chamber. For all analyses, p values were determined using one-way ANOVA (*p < 0.05; **p < 0.01; ***p < 0.001). Values represent the 
means of three independent experiments
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Fig. 3 ZEB2 binds the RAB25 promoter and represses its transcriptional activity. a Scheme representing RAB25 promoter sequence with 
E- (CANNTG) and Z-boxes (ATANNTGT). b Luciferase activity of RAB25 promoter was measured 24 h after transfection with or without ZEB2-WT or 
ZEB2 double DNA-binding mutant. pGL3 promoter activity was used as control and set as 1, and s.d is shown. c A simplified schematic of RAB25 
promoter showing localization of E/Z-boxes. Luciferase activity of RAB25 promoter WT and mutated for E/Z-boxes was measured after ZEB2 
induction (+dox). Control values were set as 1, and s.d. is shown. d HA-ZEB2 ChIP assay analyzed at different locations in the RAB25 promoter. 
Amplicons number and location are depicted on a simplified schematic of the RAB25 promoter. Enrichments to input were calculated, control 
values were set as 1 and s.d.is shown. NC negative control. For all analyses, P values were determined using two-way ANOVA (**p < 0.01; ***p < 0.001; 
ns nonsignificant). Three independent experiments were performed for all experiments
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Fig. 3d, to examine the local effect of ZEB2 on the chro-
matin status (Fig.  5b). Upon ZEB2 induction, H3K9Ac 
decreased significantly across the RAB25 promoter but 
H3K4me3 and H3K27me3 were not significantly altered 
(Fig.  5b). Additionally, knockdown of ZEB2 in MDA-
MB-231 cells significantly increased H3K9Ac, confirming 
a link between ZEB2 and H3K9Ac (Additional file 2: Fig. 
S2b).
We compared the basal levels of H3K9Ac at the 
RAB25 promoter in a series of cell lines with differential 
RAB25 expression levels (RAB25 + : MCF7 and HT29; 
RAB25-: MDA-MB-231 and BT549, Additional file  2: 
Fig.  S2c). RAB25-high cells have high H3K9Ac levels, 
and RAB25-low cells have low levels (Fig. 5c). To under-
stand how ZEB2 affects the H3K9Ac histone modifica-
tion, we focused our attention to histone deacetylases 
that are not affecting H3K27Ac but specifically regulat-
ing H3K9Ac. The available literature pointed us toward 
sirtuin family with SIRT1, which has been shown to 
strongly deacetylate H3K9Ac without affecting H3K27Ac 
[28–30]. By performing a SIRT1 ChIP assay, we showed 
that SIRT1 is significantly enriched upon ZEB2 induc-
tion (Fig.  5d), and correlated with ZEB2 recruitment 
(Fig.  3d). To see whether SIRT1 affects H3K9Ac, we 
treated ZEB2-induced cells with a SIRT1-specific inhibi-
tor (EX-527, 1 µM). This inhibitor globally prevented the 
H3K9Ac decrease caused by ZEB2, confirming a role 
for SIRT1 in H3K9 deacetylation (Fig. 5e). We extended 
these results to the EpCAM gene showing an enrichment 
of SIRT1 correlated with H3K9Ac (Additional file  2: 
Fig. S2d and e). The same was observed for CDH1 with 
H3K9Ac shift blocked by the SIRT1 inhibitor (Additional 
file 2: Fig. S2e), but SIRT1 was not significantly enriched 
(Additional file 2: Fig. S2d) suggesting that SIRT1 binds 
to another location on the CDH1 promoter. Altogether, 
these results indicate that during ZEB2-induced EMT, 
SIRT1/H3K9Ac and DNMT/DNA methylation par-
ticipate in a mechanism of repressing the expression of 
RAB25 mRNA.
SIRT1 activity maintains the stability of ZEB2‑induced 
RAB25 repression
Based on the observed associations of ZEB2, DNA meth-
ylation/DNMTs and H3K9Ac/SIRT1 with the RAB25 
promoter, we hypothesized the existence of a direct 
interaction between those nuclear proteins. Therefore, 
we performed a co-immunoprecipitation assay to pull 
down ZEB2. However, we could not pull down SIRT1 
or DNMTs (data not shown), suggesting that SIRT1 and 
DNMTs are recruited indirectly to RAB25. As SIRT1 
expression is not altered upon ZEB2 induction, regu-
lation of SIRT1 expression by ZEB2 can be ruled out 
(Fig. 6a, b). Interestingly, we observed that compared to 
control cells, SIRT1 decreased in the cytoplasmic frac-
tion but increased in the nuclear fraction in response 
to ZEB2 induction (Fig.  6c). This suggests that ZEB2 
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Fig. 4 ZEB2 increased DNA methylation at RAB25 promoter through DNMTs activity. a Correlation between RAB25 DNA methylation (x-axis) and 
ZEB2 (blue dots) or RAB25 (red dots) expression (y-axis) from publicly available NCI-60 cell panel datasets. Mean of each parameter was calculated, 
individual cell type values reported to the mean and log2 transformed. Pearson’s correlation test was used to calculate r and P values. b Global DNA 
methylation level upon ZEB2 induction (+dox) in MCF7 was measured by ELISA assay. Control values were set to 1, and s.d. is shown. P values were 
determined using unpaired t tests (***p < 0.001). c RAB25 promoter DNA methylation in MCF7 was measured by methyl-binding domain (MBD) 
assay after ZEB2 induction (+dox) and 5′-aza-2-deoxycytidine (+dox/5-aza) treatment. Enrichments to input were calculated, control values were 
set as 1 and s.d. is shown. P values were determined using one-way ANOVA (*p < 0.05). Three independent experiments were performed
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increased SIRT1 activity through an indirect mechanism 
by increasing its localization in the nucleus.
Finally, to understand the functional effect of the 
ZEB2-SIRT1-H3K9Ac association on gene repression, 
we examined RAB25 and CDH1 expression after SIRT1 
inhibition. As shown previously, upregulating ZEB2 
down-regulated RAB25 and CDH1. However, SIRT1 
inhibition is not sufficient to prevent repression of 
RAB25 and CDH1 (Fig.  6d) even when H3K9Ac pro-
tection was demonstrated (Fig.  5e). We next hypoth-
esized that deacetylation of H3K9 might stabilize 
transcriptional repression. Therefore, we induced 
ZEB2 in order to repress RAB25 and removed doxy-
cycline, which quickly stops ZEB2 transcription. After 
48 h, the levels of RAB25 and CDH1 were higher when 
SIRT1 was inhibited compared to the normal condi-
tion (Fig. 6e). We repeated the experiment and exam-
ined two time points (24  h and 48  h). We found that 
the increase in RAB25 and CDH1 was significantly 
more rapid when SIRT1 was inhibited in comparison 
to control conditions (Fig.  6f ). However, by repeat-
ing the experiment with the DNMTs inhibitor 5-aza, 
with or without the SIRT1 inhibitor, we showed no 
synergic effect but, surprisingly, decreased recovery 
a b
ed
c
Fig. 5 ZEB2 increased H3K9Ac deacetylation at RAB25 promoter through SIRT1 activity. a Immunoblotting of histone mark upon ZEB2 induction 
(+dox) in MCF7. The density of each marker was measured and represented as histograms. Expression in control was set to 1. b Histone ChIP assay 
analyzed at different localizations on RAB25 promoter after ZEB2 induction (+dox) in MCF7. c H3K9Ac ChIP assay performed in high (black) and low 
(gray) RAB25 expressing cell lines. d SIRT1 ChIP assay analyzed at different localizations on RAB25 promoter after ZEB2 induction (+dox) in MCF7. 
e H3K9Ac ChIP assay was performed after ZEB2 induction (+dox) with SIRT1 inhibitor (EX-527, 1 µM) (+dox/EX-527) in MCF7 and analyzed at 
different localizations on RAB25 promoter. For all ChIP analyses, enrichments to input were calculated, control values were set as 1 and s.d. is shown. 
NC negative control. P values were determined using two-way ANOVA (*p < 0.05; **p < 0.01; ***p < 0.001). Three independent experiments were 
performed
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of RAB25 expression (Additional file 3: Fig. S3a). One 
possible explanation is that the wider effect of 5-aza on 
gene regulation increased the expression of EMT-TFs 
such as ZEB1, SNAI1 and SNAI2 (Additional file  3: 
Fig.  S3b), which in turn repressed RAB25 when 
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Fig. 6 SIRT1 nuclear activity maintains RAB25 repression stability. a–c Expression and localization of ZEB2 and SIRT1 in MCF7 upon ZEB2 induction 
(+dox) measured by a qRT-PCR and immunoblotting from b total protein extracts or c cytoplasmic (cyto) and nuclear (nucl) extracts. SIRT1 band 
density was measured and represented as histograms. Expression in control was set to 1. d, e RAB25 and CDH1 mRNA expression were measured 
by qRT-PCR d 24 h after ZEB2 induction (+dox) with SIRT1 inhibitor (EX-527, 1 µM) (+dox/EX-527) or e 24 h after ZEB2 induction and 48 h of 
doxycycline withdrawal (+dox) with SIRT1 inhibitor (EX-527, 1 µM) (+dox/EX-527). f Kinetic of RAB25 expression measured by qRT-PCR 24 h after 
ZEB2 induction and 24 or 48 h after doxycycline withdrawal (control) with SIRT1 inhibition (EX-527, 1 µM) (+EX-527). RAB25 level at control time 
point was set to 1, and s.d is shown. For all analyses, p values were determined using two-way ANOVA (**p < 0.01;***p < 0.001; ns nonsignificant). 
Three independent experiments were performed
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EMT-TFs were overexpressed individually (Additional 
file 3: Fig. S3c).
Discussion
We show for the first time that ZEB2 induction leads to 
a strong repression of RAB25 involving an epigenetic 
mechanism encompassing DNA methylation and histone 
modification to stabilize gene repression.
Most studies on gene regulation during EMT have 
focused on CDH1, but other EMT-targeted genes have 
received inadequate attention. RAB25 is a small GTPase 
that is specifically expressed in epithelial cells [21] as con-
firmed in our analysis and down-regulated during EMT 
[11, 12]. RAB25 expression is altered in many cancer 
types (e.g., breast, colorectal, ovarian and lung). Intrigu-
ingly, it has been described as having both pro- and 
anti-tumorigenic properties, influencing proliferation 
and cell migration [12, 14, 16–20]. We observed RAB25 
opposite function in our cell lines as specific knockdown 
of RAB25 altered migratory properties of A431 cells but 
had no effect on MCF7 cells (data not shown). How-
ever, in the EMT context the role of RAB25 seems to be 
more consistent. In ZEB2-induced EMT, RAB25 down-
regulation facilitates migration of cell lines from differ-
ent origins, such as luminal-like (MCF7) or claudin-low 
(MDA-MB-231) breast cancer cells, and skin squamous 
carcinoma (A431) or colorectal cancer cells (HT29). 
It would be interesting to know whether the RAB25 
migratory effect also applies to other EMT-TFs, because 
they are usually co-expressed and work in concert. The 
pro-migratory effect of RAB25 observed in some cel-
lular models is more dependent on the cellular context 
for the expression of specific RAB25-partners as CLIC3 
[31]. However, in tumors which contain a mosaic of cells 
with different phenotypes, EMT-mediated and specific 
RAB25-mediated migration could work in concert, with 
EMT-positive cells at the edge of the tumor leading the 
way for RAB25-positive epithelial cells cooperating to 
promote tumor progression. Another functional effect of 
RAB25 expression could be the induction of mesenchy-
mal-to-epithelial transition (MET) at disseminated can-
cer cell secondary sites and promotion of colonization, as 
proposed by Mitra and colleagues [12].
Understanding EMT-regulatory mechanisms that 
repress genes such as RAB25 could identify new thera-
peutic targets to reverse EMT-associated properties, for 
example, metastasis, stemness and chemoresistance. Re-
expressing RAB25 might not only affect the migratory 
properties as mentioned earlier but could also lead to the 
sensitization of cancer cells to specific therapies. Due to 
the physiological role of RAB25 in apical recycling, it has 
been associated with speed of EGFR recycling [32], mak-
ing cells more sensitive to EGFR-targeted therapies such 
as gefitinib [33]. However, targeting nuclear factors as 
EMT-TFs is difficult, and other strategies are needed to 
disrupt the EMT-regulatory network. An appealing alter-
native approach is to target essential EMT-TFs cofac-
tors such as chromatin-remodeling enzymes to restore 
expression of RAB25.
The link between EMT and epigenetic regulation 
was described a decade ago [34, 35] and is increasingly 
pointed to an important aspect upstream and down-
stream of the EMT-regulatory network [8]. During 
EMT, the epigenome of cells is drastically altered by 
hypermethylation, associated with repressive histone 
marks (H3K27me3), of epithelial genes such as CDH1 
or GRHL2. In contrast, mesenchymal genes showed 
hypomethylation of the promoter and/or gene body 
hypermethylation associated with active histone marks 
(H3K4me3/H3K9Ac), as described for TCF4 [11, 36–40]. 
Our study sheds light on the specific effect of ZEB2 on 
gene regulation. We showed that upon ZEB2 induc-
tion, there is considerable global hypermethylation and 
a shift of active to repressive histone marks, resulting in 
a general repressed chromatin. To try to understand this 
repressive shift, we turned our attention to the activities 
of DNMTs and SIRT1.
DNMTs have been linked with EMT-TFs function, and 
a direct interaction of DNMT1 with SNAI1/2 and ZEB1 
factors has been demonstrated [41–43]. ZEB2 was pre-
viously shown to require DNMTs activity to function in 
embryonic stem cell differentiation [44], but there was no 
direct evidence for the interaction of ZEB2 with DNMTs. 
In our models, we found no evidence for a direct inter-
action between ZEB2 and DNMTs. The effect of DNA 
methylation on gene regulation during EMT has been 
reported mainly for CDH1, and there is some discrep-
ancy between the studies [42, 45]. Fukagawa and col-
laborators showed in a panel of breast cancer cell lines 
that CDH1 has different levels of methylation that cor-
relate with ZEB1 and ZEB2 expression levels [42]. Treat-
ment of cells having low CDH1 expression with 5-aza is 
not enough to revert CDH1 repression but requires that 
ZEB1 and ZEB2 have to be knocked down to strongly 
restore CDH1 expression. Our study is consistent with 
these results, as 5-aza alone was not enough to restore 
RAB25 and CDH1 expression. In other studies, treatment 
with 5-aza was enough to revert CDH1 repression, and 
it has been described as an anti-EMT drug [45]. In other 
studies, 5-aza treatment induced EMT [46]. From a ther-
apeutic perspective, these conflicting findings show that 
5-aza treatment is a double-edged sword. In some tumor 
types, it blocked EMT and tumor progression [46, 47], 
while in others induced EMT-TFs expression and EMT 
[45], like we observed in the induction of SNAI1, SNAI2 
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and ZEB1 expression in MCF7 cells after 5-aza treatment 
alone or in combination with the SIRT1 inhibitor.
The second significant effect of ZEB2 induction on epi-
genetic modification was the deacetylation of H3K9 by 
SIRT1 deacetylase. SIRT1 resides in the nucleus where it 
deacetylates histones (e.g., H4K16 and H3K9) and non-
histone proteins (e.g., KU70; p53…) [28, 29]). SIRT1 ele-
vation has been associated with tumor progression and 
a worse prognosis in several cancer types (e.g., bladder, 
breast, hepatocellular carcinoma, gastric, and pancreatic 
cancer) [48–53]. In vitro and in vivo experiments linked 
the induction of SIRT1 to an increase in cell prolifera-
tive and migratory properties inversely correlated with 
CDH1 expression [48, 54–56]. As suspected with CDH1 
down-regulation, SIRT1 pro-migratory property has 
been linked with EMT and has been an essential actor 
for the TGF-β-induced EMT [52, 53, 57–59]. Mechanis-
tically, SIRT1 interacts with ZEB1 and MPP8 to repress 
CDH1 gene expression [60, 61]. Our data show that com-
pared to ZEB1, ZEB2 cannot interact with SIRT1 even if 
both of them are enriched at the same RAB25 promoter 
region. We can exclude the regulation of SIRT1 by ZEB2 
as we could not see differences in expression level but an 
increase in SIRT1 in the nucleus of cells expressing ZEB2. 
Several possible scenarios can explain the indirect effect 
of ZEB2 on SIRT1 and DNMTs actions, as (i) the mod-
ulation of signaling pathways affecting enzymes activ-
ity and localization (ii) the creation of early DNA marks 
recruiting epigenetic complex containing SIRT1 and 
DNMTs in a second wave or (iii) through the regulation 
of SIRT1 and DNMTs partners, promoting and/or dictat-
ing DNA interaction specificity.
Another surprising result in our model came from 
the use of 5-aza with or without SIRT1 inhibition, which 
reversed DNA methylation and histone deacetylation 
but did not prevent RAB25 and CDH1 repression. These 
observations with the fact that ZEB2 is not directly 
recruiting DNMTs and SIRT1 point to a secondary regu-
latory event, whereby epigenetic modifications strengthen 
long-term gene repression but are not essential for the 
ZEB2 repressive function. However, EMT-TFs function 
dependency against epigenetic enzyme activity might be 
important for another protein complex. Such is the case 
for ZEB2 and LSD1, where inhibiting LSD1 or blocking 
the interaction partially prevents ZEB2-induced EMT [9], 
and for SNAI1 and EZH2, where targeting the long non-
coding HOTAIR prevents SNAI1-EZH2 interaction and 
hepatocyte transdifferentiation through EMT [62]. Epige-
netic enzymes other than LSD1 could be more important 
for ZEB2 functions. Investigating this possibility requires 
deciphering the entire ZEB2 interactome, especially in the 
earliest steps of ZEB2 activation, to fully be able to disrupt 
ZEB2 repressive and activating functions.
Materials and methods
Cell culture and cell models
A431, HT29 and MDA-MB-231 cells were grown in 
Dulbecco’s modified Eagle’s medium containing 4.5  g/l 
glucose (Gibco, Thermo Fisher Scientific, Bleiswijk, 
the Netherlands) supplemented with 10% fetal bovine 
serum (Bodinco, Alkmaar, the Netherlands) and 2  mM 
l-glutamine (Lonza, Verviers, Belgium). MCF7 cells were 
grown in Dulbecco’s modified Eagle’s medium contain-
ing 4.5  g/l glucose (Gibco, Life Technologies) supple-
mented with 5% fetal bovine serum (Bodinco), 0.01 mg/
ml human recombinant insulin, 2  mM l-glutamine 
(Lonza), 1 mM sodium pyruvate (Sigma-Aldrich, Overi-
jse, Belgium), and 1X non-essential amino acids (Lonza). 
All media contained 100 U/ml penicillin/streptomycin 
(Gibco, Llife Technologies), and cells were grown at 37 °C 
in an incubator in a 5%  CO2 atmosphere.
Cellular models with conditional ZEB2 expres-
sion were obtained following the stable transduction 
of MCF7, HT-29 and A431 cells with a pSIN vector 
encoding ZEB2 ORF linked to the hemagglutinin (HA) 
tag and also encoding green fluorescent protein (GFP) 
to select transduced cells by flow cytometry. Clones 
were isolated and selected based on ZEB2 induc-
tion level upon doxycycline treatment. MDA-MB-231 
ZEB2-KD cells were obtained following the stable 
transduction of pLVTH vector encoding ZEB2 shRNA 
(GGA GCT GGG TAT TGT TAA A) and also GFP. The 
empty vector (pLVTH) was used to generate control 
cells.
Transwell migration assays
A transwell migration assay was performed in Boyden 
chamber 24 transwell plates (8  µm pores, Corning, 
Sigma-Aldrich). Two days before the experiment, the 
cells were transfected, by using FuGENE HD (Promega, 
Leiden, the Netherlands), according to the manufactur-
er’s instructions, with (1) pWPI vector encoding RAB25 
ORF in the MCF7 and A431 ZEB2-inducible cell models 
or (2) pLVTH vector encoding a shRNA specifically tar-
geting RAB25 (GGC CCG AAT GTT CGC TGA A) in the 
MDA-MB-231 ZEB2-KD cell model. The empty vector 
(pWPI or pLVTH) was transfected in parallel and used 
as control. After 24  h, the media were removed and 
replaced with media containing 2% FBS with or with-
out doxycycline. After another 24  h, 5 × 104 cells were 
seeded in the top chamber, while the lower chamber 
contained full medium to serve as chemoattractant, and 
maintained for 24 h. The cells on the lower surface were 
fixed, stained with DAPI, and counted using a fluores-
cent microscope. Each experiment was performed at 
least three times.
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Chromatin immunoprecipitation (ChIP)
For histone marks, 1 × 106 cells were used per ChIP, while 
2.5 × 106 cells were used for HA and SIRT1 ChIP. Briefly, 
the cells were cross-linked with 1% paraformaldehyde in 
fixation buffer (Active Motive, La Hulpe, Belgium). After 
the isolation of the nuclei, DNA was fragmented with 25 
U micrococcal nuclease for 30 min at 37 °C in micrococ-
cal nuclease-digesting buffer (50  mM Tris–HCl pH 7.6, 
1  mM  CaCl2 and 0.05% Triton X-100). DNA fragment 
size (150-500  bp) was confirmed in a 1.2% agarose gel. 
The fragmented chromatin was incubated overnight at 
4 °C with 5 µg anti-HA (ab9110, Abam, Cambridge, UK) 
or anti-SIRT1 (07-131 EMD Millipore, Sigma-Aldrich) 
or for 6  h at 4  °C with 3  µg anti-H3K27me3 (39155), 
anti-H3K4me3 (39159) or anti-H3K9ac (39917) (Active 
Motive), followed by the pull-down of protein–DNA 
complexes with A/G-conjugated magnetic beads for 
1 h (EMD Millipore, Sigma-Aldrich). After the cleaning 
steps, DNA was purified with iPure V2 kit following the 
manufacturer’s protocol (Diagenode, Liège, Belgium).
DNA methylation ELISA and Methyl‑Binding Domain (MBD) 
assay
DNA was isolated from the cells with the DNeasy Blood 
and Tissue kit (Qiagen, Venlo, the Netherlands). Global 
DNA methylation was measured by ELISA with the 
fluorometric MethylFlash Methylated DNA 5-mC quan-
tification kit (Epigentek, Farmingdale, NY, USA) follow-
ing manufacturer’s protocols. Specific RAB25  promoter 
methylation was measured after DNA methylation pull-
down using MethylCap kit (Diagenode). Briefly, 1ug of 
DNA was sheared to generate fragments around 400 bp 
and was confirmed on a 1.2% agarose gel. Sheared DNA 
was incubated for 2  h at 4  °C with MethylCap protein, 
which will specifically bind to methylated DNA, followed 
by the pull-down of protein-DNA complex with mag-
netic meDNA capture beads provided in the kit. After 
cleaning steps, DNA was removed from the beads with 
High Elution buffer and analyzed by qPCR.
Promoter isolation and reporter assays
The human RAB25 promoter sequence was identified by 
screening public human genomic DNA databases (http://
genom e.ucsc.edu and http://www.ensem bl.org). This 
sequence was aligned to orthologous sequences of mul-
tiple species using Mulan (http://mulan .dcode .org), and 
evolutionarily conserved transcription factor binding 
sites were identified. The human promoter sequence was 
amplified by PCR from genomic DNA (primers: 5′-GTG 
CTG GGA TTA CAG GCG TGAG-3′ and 5′-CTG GTC 
CTG CCC CTC CTC TCAT-3′. The 454-bp amplicon was 
first cloned in pCR-BluntII-TOPO (Thermo Fisher Scien-
tific) and then subcloned in pGL3basic (Promega) using 
KpnI and XhoI. Mutagenesis of the putative ZEB2-bind-
ing sites in the human RAB25 promoter sequence was 
performed with the QuickChange Multi Site-Directed 
Mutagenesis Kit (Agilent Technologies, Machelen, Bel-
gium) using three primers, each mutated in the puta-
tive ZEB2-binding sequence: (1) mutant primer E-box 1 
(CAC CTG sequence): 5′-ATC TCT CCA CCC ATCTG 
GGC CCC AGG TCT C-3′;(2) mutant primer E-box  2 
(CAC CTG sequence): 5′-TTA CAG CAC CCC CATCTG 
CCA GAG CTG ATC-3′; (3) and mutant primer Z-box1/2 
(ACCTG sequences): 5′-CCC AAC TTGT CGA ACTTGT 
CTG ACG TCA TC-3′.
Transient transfection of the luciferase reporter con-
struct in MCF7-ZEB2 cells and cotransfection with wild-
type ZEB2 (pCS3SIP1FS) or ZEB2-DNA binding mutant 
expression vector (pCS3SIP1NZF3/CZF3-Mut) in paren-
tal MCF7 cells were performed using FuGENE HD fol-
lowing the manufacturer’s protocol (Promega). One day 
after transfection, the cells were treated with doxycycline 
(1  µg/ml) to induce ZEB2. After 48  h, luciferase activ-
ity was measured by using One-GLO luciferase assay 
according to the manufacturer’s protocol (Promega).
Epigenetic inhibitors
The cells were treated for 24 h with 1 µM SIRT1 inhibitor 
(EX-527) and/or 1  µM 5-aza-2′-deoxycytidine (Sigma-
Aldrich) along with doxycycline (1 µg/ml). To study the 
direct effect of the epigenetic inhibitor on gene expres-
sion, RNA was extracted after 24  h of treatment. To 
recover gene expression, the media were replaced with 
doxycycline-free media for another 24 and 48  h before 
RNA extraction.
Quantitative PCR
Total RNA from cells was prepared using the Rneasy mini 
kit (Qiagen), and cDNA was prepared with  SensiFastTM 
cDNA synthesis kit (Bioline, GC Biotech, Waddinxveen, 
the Netherlands) following manufacturer’s protocols. 
Quantitative PCR was performed using  SensiFASTTM 
SYBR no-rox kit following the manufacturer’s protocol 
in a LightCycler real-time PCR system (Roche Diagnos-
tics, Vilvoorde, Belgium). Primer information is given in 
Table  1. Each marker was assayed in triplicate in three 
independent experiments. The expression levels of the 
genes of interest were normalized to the mRNA level of 
the HPRT housekeeping gene.
Protein extraction and western blotting
Total proteins were extracted with RIPA buffer (50 mM 
Tris–HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate and 0.1% SDS) containing  HaltTM pro-
tease and phosphatase inhibitor cocktail (Thermo Fisher 
Scientific). Cytoplasmic proteins were extracted in 
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hypo-osmotic buffer (20 mM HEPES pH 7.6, 10 mM KCl, 
2 mM  MgCl2, 1 mM EDTA/EGTA) with 0.1% Tween-20 
containing Halt™ protease and phosphatase inhibitor 
cocktail (Thermo Fisher Scientific) and passed 5 times in 
a 25G needle. After centrifugation, the supernatant con-
tained cytoplasmic extract, while the nuclear pellet was 
lysed with RIPA buffer. To extract histones, the nucleus 
was first purified (1X PBS, 0.5% Triton X-100 and 5 mM 
sodium butyrate) followed by acid extraction (0.4 M HCl) 
for 1  h at 4  °C. Acid was neutralized with 2.5× of 1  M 
 Na2HPO4. For histone marks, 1  µg of histone extract 
was separated in a 15% gel, and 20  µg of total protein 
extract was separated on a 10% gel. The following anti-
bodies were used for blotting: H3K27ac (39133), H3K9ac 
(39917), H3K4me3 (39159), H3K27me3 (39155) (Active 
Motive), HA (16B12, BioLegend), RAB25 (D4P6P—Cell 
Signaling Technologies, Leiden, the Netherlands), SIRT1 
(07-131, Millipore), HDAC1 (ab7028, Abcam) and beta-
tubulin (TUB 2.1) (Sigma-Aldrich).
Gene expression database analysis
ZEB2 and RAB25 expression data were extracted from 
publicly available datasets from two independent studies 
on the NCI-60 cell panel (GSE32474 and GSE29288) and 
from the Cancer Cell Encyclopedia (GSE36133). To study 
the methylome, we used the NCI-60 Methylome data-
set (GSE49143) and focused on the four probes located 
at or near the promoter region of RAB25 (cg02448190, 
cg09243900, cg15896939 and cg19580810). For each 
dataset, the expression or methylation level of each cell 
line was compared to the average expression or methyla-
tion level of the dataset and log-transformed. Log values 
were plotted to analyze the correlation between the two 
parameters.
Statistical analysis
Statistical analysis was performed using the Graphpad 
Prism 7.01 software (Graphpad Softwares Inc.). Differ-
ences between two samples were analyzed by Student’s t 
test or by ANOVA with selected comparison using Tuk-
ey’s post hoc test. Differences were considered significant 
for p values < 0.05. For correlation analysis, Pearson cor-
relation was performed.
Additional files
Additional file 1: Figure S1. ZEB2 and RAB25 correlation is dependent 
of the cancer type. Correlation between ZEB2 (y-axis) and RAB25 (x-axis) 
expression from CCLE cell panel datasets analyzed for (a, b) breast (c) 
colon (d) pancreas, (e) small-cell lung, (f) skin and (g) non-small-cell lung 
cancer cells. Mean of each parameter was calculated, individual cell type 
values reported to the mean and log2 transformed. Pearson’s correlation 
test was used to calculate r and p values. 
Additional file 2: Figure S2. CDH1 and EpCAM are targeted by ZEB2 and 
SIRT1 modulating H3K9Ac level. (a) HA-ZEB2 ChIP assay after induction 
(+dox) analyzed on CDH1 and EpCAM promoter location using published 
sequences. (b) H3K9Ac ChIP assay performed in MDA-MB-231, 48 h after 
ZEB2 siRNA treatment (siZEB2). (c) RAB25 mRNA expression measured 
by qRT-PCR in HT29, MCF7, BT549 and MDA-MB-231. P values were 
determined using two-way ANOVA (***p < 0.001). (d) SIRT1 ChIP and (e) 
H3K9Ac ChIP assay performed after ZEB2 induction (+dox) with SIRT1 
inhibitor (EX-527, 1 μM) (+dox/EX-527), in MCF7 analyzed on CDH1 and 
EpCAM promoter. Enrichments to input were calculated, control values 
were set as 1 and s.d. is shown. For all analyses, p values were determined 
using two-way ANOVA (*p < 0.05; **p < 0.01). NC = negative control. Three 
independent experiments were performed for all experiments. 
Additional file 3: Figure S3. DNMT inhibitor 5-aza-2′-deoxycytidine de-
repressed ZEB1, SNAI1 and SNAI2 EMT-TFs which targeted RAB25 expres-
sion. (a) RAB25 and CDH1 mRNA expression were measured by qRT-PCR 
48 h after doxycycline withdrawal (+dox off ) with 5-aza-2′-deoxycytidine 
(1 μM) (+dox/5-aza) and SIRT1 inhibitor (EX-527, 1 μM) (+dox/5-aza/
EX-527). P values were determined using two-way ANOVA (***p < 0.001). 
b EMT-TFs expressions (ZEB2, ZEB1, SNAI1 and SNAI2) were measured by 
qRT-PCR 24 h after 5-aza-2′-deoxycytidine (1 μM) (+ 5-aza) and/or SIRT1 
inhibitor (EX-527, 1 μM) treatments (+ EX-527 and +5-aza/EX-527). P 
values were determined using two-way ANOVA (***p < 0.001). (c) RAB25 
mRNA expression was measured by qRT-PCR 48 h after ZEB1, SNAI1 and 
SNAI2 induction (+dox) in MCF7. P values were determined using t test 
(***p < 0.001).
Abbreviations
5-aza: 5-aza-2′-deoxycytidine; ChIP: chromatin immunoprecipitation; Dox: 
doxycycline; DNMT: DNA methyl transferase; EMT: epithelial-to-mesenchymal 
Table 1 Primer set for qRT-PCR and ChIP-PCR
Gene Primer sequences 5′ to 3′
ZEB2 CGA GCG GCA TAT GGT GAC A
GCC ACA CTC TGT GCA TTT GAA 
RAB25 CTC AGC CCT GGA CTC TAC CAA 
TCC GGA TGC TGT TCT GTC TCT 
CDH1 CGG TTC CGA AGC TGC TAG TC
TTG AAG CGA TTG CCC CAT T
EpCAM GCG GCT CAG AGA GAC TGT G
CCA AGC ATT TAG ACG CCA GTTT 
VIM1 GAC AAT GCG TCT CTG GCA CGT CTT 
TCC TCC GCC TCC TGC AGG TTCTT 
SIRT1 TGT GTC ATA GGT TAG GTG GTGA 
AGC CAA TTC TTT TTG TGT TCGTG 
HPRT TGA CAC TGG CAA AAC AAT GCA 
GGT CCT TTT CAC CAG CAA GCT 
ChIP_RAB25_1 ACC TCA GCC TCC CAA AGT 
TGA GGG CTG AGT GTG CAT 
ChIP_RAB25_2 CCC AGC AAT GCA CAC TCA 
TGG GTG GAG AGA TGA TGA CG
ChIP_RAB25_3 GAC ACC CAA CCT GTC GAA CCT 
CGG AAG CTG AGA ACA GGA AGA 
ChIP_RAB25_4 TTT GAG AGC TGA GGG TTG AG
ATC TTC CTC AGT TCC ATT CCC 
ChIP_CDH1 GGC CGG CAG GTG AAC 
GGG CTG GAG TCT GAA CTG AC
ChIP_EpCAM TAG CCT CCA CGT TCC TCT ATCC 
TGC TGA GAC TTC CTT TTA ACCG 
ChIP_NC CAC TAC GCC TGG CTA ATT T
TCA GGA GAT CGA GAC CAT C
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transition; EMT-TF: EMT transcription factor; HA: hemagglutinin; TGF-β: trans-
forming growth factor beta; ZEB: zinc-finger E-box binding homeobox.
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